PANDAS

---

title: "PANDAS" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["central-nervous-system-disorders", "autoimmune-diseases", "tourette-syndrome", "biology-of-attention-deficit-hyperactivity-disorder", "biology-of-obsessive–compulsive-disorder", "psychiatry-controversies", "neurological-disorders-in-children"] description: "Hypothesis in pediatric medicine" topic_path: "science/biology" source: "https://en.wikipedia.org/wiki/PANDAS" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Hypothesis in pediatric medicine ::

::data[format=table title="Infobox medical condition (new)"]

Field	Value
name	Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections
image	Streptococcus pyogenes 01.jpg
caption	Streptococcus pyogenes (stained red), a common group A streptococcal bacterium. PANDAS is speculated to be an autoimmune condition in which the body's own antibodies to streptococci attack the basal ganglion cells of the brain, by a concept known as molecular mimicry.
field	Neurology, Psychiatry
::

::callout[type=note]

::

| name = Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections | synonyms = | image = Streptococcus pyogenes 01.jpg | alt = | caption = Streptococcus pyogenes (stained red), a common group A streptococcal bacterium. PANDAS is speculated to be an autoimmune condition in which the body's own antibodies to streptococci attack the basal ganglion cells of the brain, by a concept known as molecular mimicry. | pronounce = | field = Neurology, Psychiatry | symptoms = | complications = | onset = | duration = | types = | causes = | risks = | diagnosis = | differential = | prevention = | treatment = | medication = | prognosis = | frequency = | deaths =

Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) is a controversial hypothetical diagnosis for a subset of children with rapid onset of obsessive–compulsive disorder (OCD) or tic disorders. Symptoms are proposed to be caused by group A streptococcal (GAS), and more specifically, group A beta-hemolytic streptococcal (GABHS) infections. OCD and tic disorders are hypothesized to arise in a subset of children as a result of a post-streptococcal autoimmune process. The proposed link between infection and these disorders is that an autoimmune reaction to infection produces antibodies that interfere with basal ganglia function, causing symptom exacerbations, and this autoimmune response results in a broad range of neuropsychiatric symptoms.

The PANDAS hypothesis, first described in 1998, was based on observations in clinical case studies by Susan Swedo et al. at the US National Institute of Mental Health and in subsequent clinical trials where children appeared to have dramatic and sudden OCD exacerbations and tic disorders following infections.

There is no diagnostic test to accurately confirm PANDAS; the diagnostic criteria are unevenly applied and the conditions may be overdiagnosed. Treatment for children suspected of PANDAS is generally the same as the standard treatments for Tourette syndrome (TS) and OCD. There is insufficient evidence or consensus to support treatment, although experimental treatments are sometimes used, and adverse effects from unproven treatments are expected. The media and the internet have contributed to an ongoing PANDAS controversy, with reports of the difficulties of families who believe their children have PANDAS or PANS. Attempts to influence public policy have been advanced by advocacy networks.

Characteristics

The children originally described by Susan Swedo et al. (1998) usually had an abrupt onset of symptoms, including motor or vocal tics, obsessions, or compulsions. In the PANDAS model, this abrupt onset is thought to be preceded by a strep throat infection. As the clinical spectrum of PANDAS appears to resemble that of Tourette syndrome (TS or TD, for Tourette's disorder), some researchers hypothesized that PANDAS and TS may be associated; this idea is challenged and a focus for research.

Pediatric acute-onset neuropsychiatric syndrome (PANS) is a hypothesized disorder characterized by the sudden onset of OCD symptoms or eating restrictions, concomitant with acute behavioral deterioration or severe neuropsychiatric symptoms including sleep, emotional and behavioral disturbances, regression in school performance, or motor and sensory issues. PANS eliminated tic disorders as a primary criterion and placed more emphasis on acute-onset OCD, while allowing for causes other than streptococcal infection.

Classification

::figure[src="https://upload.wikimedia.org/wikipedia/commons/a/aa/Proposed_PANDAS.svg" caption="pmc=3181902 }}" alt="OCD and chronic tic disorders intersect but neither is a subset of the other. Tic-related OCD is their intersection. PANDAS is a small subset of the union of OCD and tic disorders, and is in all three subregions of their union."] ::

PANDAS is hypothesized to be an autoimmune disorder that results in a variable combination of tics, obsessions, compulsions, and other symptoms with sudden or abrupt onset that may be severe enough to qualify for diagnoses such as chronic tic disorder, OCD, and TS.

PANS, CANS and PITANDs are also hypothesized to be autoimmune disorders.

Cause

The PANDAS diagnosis and the hypothesis that symptoms in this subgroup of patients are caused by infection are disputed and unconfirmed. The cause is thought to be akin to that of Sydenham's chorea (SC), which is known to result from childhood group A streptococcal (GAS) infection leading to the autoimmune disorder rheumatic fever of which SC is one manifestation. Like SC, PANDAS is thought to involve autoimmunity to the brain's basal ganglia.

To establish that a disorder is an autoimmune disorder, the Witebsky criteria require

1. that there be a self-reactive antibody,
2. that a particular target for the antibody is identified (autoantigen),
3. that the disorder can be caused in animals, and
4. that transferring antibodies from one animal to another triggers the disorder (passive transfer).

Results of studies investigating an autoimmune cause that meet Witebsky's criteria are inconsistent, controversial, and subject to methodological limitations.

To show that a microorganism causes a disorder, the Koch postulates would require one show that the organism is present in all cases of the disorder, that the organism can be extracted from those with the disorder and be cultured, that transferring the organism into healthy subjects causes the disorder, and the organism can be re-isolated from the infected party. Giavanonni notes that the Koch postulates are not useful in substantiating PANDAS a post-infectious disorder because the organism may no longer be present when symptoms emerge, multiple organisms may cause the symptoms, and the symptoms may be a rare reaction to a common pathogen.

Some studies support acute exacerbations associated with streptococcal infections among clinically defined PANDAS subjects; others studies have found no association between abrupt onset or exacerbation with infection. The PANS hypothesis, then, expands the causes beyond streptococcal infection and postulates that the cause can be genetic, metabolic, or infectious.

Among children with PANS or PANDAS, studies are inconsistent, and the hypothesis that antibodies trigger symptoms is unproven; some studies showed antibodies in children with PANS/PANDAS, but those results were not replicated in other studies. A consensus statement from the British Paediatric Neurology Association (BPNA), states that a "causal infection (rather than coincidental infection) or an inflammatory or autoimmune pathogenesis" has not been confirmed, and that "no consistent biomarkers have been identified that accurately diagnose PANDAS or are reliably associated with brain inflammation".

Mechanism

The mechanism is hypothesized to be similar to that of rheumatic fever, an autoimmune disorder triggered by streptococcal infections, where antibodies attack the brain and cause neuropsychiatric conditions. In a typical bacterial infection, the body produces antibodies against the invading bacteria, and the antibodies help eliminate the bacteria from the body. In some rheumatic fever patients, autoantibodies may attack heart tissue, leading to carditis, or cross-react with joints, leading to arthritis. In PANDAS, it is believed that tics and OCD are produced in a similar manner. One part of the brain that may be affected in PANDAS is the basal ganglia, which is believed to be responsible for movement and behavior. It is thought that similar to Sydenham's, the antibodies cross-react with neuronal brain tissue in the basal ganglia to cause the tics and OCD that characterize PANDAS.

It is unclear if the group of patients diagnosed with PANDAS developed tics and OCD through a different mechanism than seen in other people diagnosed with TS. Studies are inconsistent: the strongest supportive evidence comes from a controlled study of 144 children (Mell et al., 2005), but prospective longitudinal studies have not produced conclusive results, and other studies do not support the hypothesis.

Diagnosis

Neither PANDAS nor PANS are listed as a diagnosis in the 2013 fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) or confirmed as distinct disorders. PANDAS is mentioned in the World Health Organization's ICD-11, effective in 2022, under autoimmune central nervous system disorders, but diagnostic criteria are not defined and no specific code for PANS or PANDAS is given. The 2021 European clinical guidelines developed by the European Society for the Study of Tourette syndrome (ESSTS) did not support the additions made to ICD-11.

Swedo et al. in their 1998 paper proposed five diagnostic criteria for PANDAS: "(1) the presence of a tic disorder and/or OCD consistent with DSM-IV; (2) prepubertal onset of neuropsychiatric symptoms; (3) a history of a sudden onset of symptoms and/or an episodic course with abrupt symptom exacerbation interspersed with periods of partial or complete remission; (4) evidence of a temporal association between onset or exacerbation of symptoms and a prior streptococcal infection; and (5) adventitious movements (e.g., motoric hyperactivity and choreiform movements) during symptom exacerbation".

The proposed PANS criteria call for abrupt onset of OCD (severe enough to warrant a DSM diagnosis) or restricted food intake, along with severe and acute neuropsychiatric symptoms from at least two of the following: anxiety, emotional lability or depression, irritability or oppositional behaviors, developmental regression, academic deterioration, sensory or motor difficulties, or sleep or urinary disturbances. The symptoms should not be better explained by another disorder, such as Syndenham's chorea or Tourette syndrome. The authors stated that all other causes must be excluded (diagnosis of exclusion) for PANS to be considered.

There is no diagnostic test to accurately confirm PANDAS. and erratum based on collection tubes.}}

PANDAS may be overdiagnosed: the diagnostic criteria are unevenly applied and a presumed diagnosis may be conferred in "children in whom immune-mediated symptoms are unlikely",

Because symptoms overlap with many other psychiatric conditions, differential diagnosis is challenging. There are several difficulties in distinguishing PANDAS from TS. The two have a similar onset and waxing and waning course, and the sudden onset or exacerbation in tics hypothesized in PANDAS is not uncommon in TS. There is a higher rate of OCD and TS among relatives of children with PANDAS, and those children often have tics preceding a PANDAS diagnosis or may be predisposed to tic disorders; what appears to be a dramatic onset due to GAS infection "may be the natural course of tic disorders", according to Ueda and Black (2021).

Treatment

Treatment for children suspected of PANDAS is generally the same as the standard treatments for TS and OCD. These include cognitive behavioral therapy and medications to treat OCD such as selective serotonin reuptake inhibitors (SSRIs); and "conventional therapy for tics".

When individuals have "persistent or disabling symptoms", Wilbur (2019) et al. recommend referral to specialists, treatment of identified acute streptococcal infections according to established guidelines, and immunotherapy only in clinical trials.

The use of psychotropic medications for PANS/PANDAS is widespread, although controlled trials were lacking .

Experimental

Prophylactic antibiotic treatments for tics and OCD are experimental and their use is challenged; overdiagnosis of PANDAS may have led to overuse of antibiotics to treat tics or OCD in the absence of active infection. Evidence for antibiotic treatment is inconclusive for PANS, PANDAS, PITAND and CANS. Murphy, Kurlan and Leckman (2010) said, "The use of prophylactic antibiotics to treat PANDAS has become widespread in the community, although the evidence supporting their use is equivocal."

, there is no evidence supporting the use rituximab or mycophenolate mofetil for treating PANDAS/PANS.

There is inconclusive evidence supporting immunomodulatory therapies (intravenous immunoglobulin (IVIG) or therapeutic plasma exchange (TPE)

Studies of experimental treatments for PANS and PANDAS (IVIG, TPE, antibiotics, tonsillectomy, corticosteroids and NSAIDs) are "few and in general have moderate or high risk of bias", according to a Sigra et al. review published in 2018, which states:

Guidelines

Following a 2014 meeting in the US of Swedo and physicians from Stanford University, In a 2018 review, Sigra et al. said of the 2017 guidelines that treatment consensus was lacking and that results were inconclusive. A 2019 review by Wilbur et al. said that evidence for treatment of children with PANDAS/PANS is lacking, and remission rates in symptoms after treatment "may represent the natural history of [non-PANDAS pediatric OCD] cases rather than true treatment effect". The Wilbur et al. 2019 review found no evidence to support tonsillectomy or prophylactic antibiotics, recommended standard approved therapies known to be effective for OCD, and cautioned against immunomodulatory therapies except in clinical trials. Gilbert (2019) stated: "Skeptics have concluded that treatment studies do not support antibiotic or immunomodulatory interventions for PANDAS. Advocates published treatment guidelines supporting both." Gilbert adds that "... if PANS/PANDAS is really common, the best approach will have to be large, randomized, placebo-controlled trials. In addition, it would behoove skeptics and advocates to collaborate in pursuing both good science and sound patient care, while eschewing pseudoscientific approaches and calling out profit-seeking behaviors such as cash-pay clinics, Internet diagnoses, and expert witness testimony."

The guideline status in the UK is similar. The PANDAS and PANS Physicians Network published guidelines in 2018 on a private healthcare platform, e-hospital. In April 2021, the British Paediatric Neurology Association (BPNA) issued a consensus statement with the Child and Adolescent Psychiatry Faculty of the Royal College of Psychiatrists stating that there is an absence of evidence for recommending immunomodulatory or prophylactic antibiotic treatments. This consensus statement was issued in place of a guideline as the authors stated that there was insufficient evidence for developing a typical guideline. It noted no previous guidelines for PANDAS existed or had been endorsed by official bodies in the UK, including the National Institute for Health and Care Excellence (NICE), and that the 2018 guidelines available at a PANDAS/PANS UK charity website and the private platform (e-hospital) had been developed independently of the BPNA.

Similarly, the April 2021 treatment guidelines for Nordic countries (Denmark, Norway, Sweden and the UK) do not recommend tonsillectomy, antibiotic prophylaxis, or experimental immunomodulatory therapies outside of a specialist setting. A Swedish review published in 2021 found a moderate potential for adverse effects, and a "very low certainty of evidence of beneficial effects", for treating individuals meeting the research definition of PANS with antibiotics, anti-inflammatory medications, or immunomodulatory agents. The Swedish review states that, "some researchers in the United States, on the basis of an assumption of an underlying neuroinflammation, recommend anti-inflammatory drugs, antibiotics and immunomodulatory treatment in the clinical management of these patients, Swedish national guidelines imply that these treatments shall only be provided within the framework of research and development".

The American Academy of Neurology (AAN) 2011 guidelines say there are "inadequate data to determine the efficacy of plasmapheresis" and "insufficient evidence to support or refute the use of plasmapheresis", for treating OCD and tics "in the setting of PANDAS". The Medical Advisory Board of the Tourette Syndrome Association (now the Tourette Association of America) said in 2006, and reiterated in 2021: The American Heart Association's 2009 guidelines state that they do "not recommend routine laboratory testing for GAS to diagnose, long-term antistreptococcal prophylaxis to prevent, or immunoregulatory therapy (such as intravenous immunoglobulin, plasma exchange) to treat exacerbations of this disorder".

In Lyme disease guidelines released in 2020, experts from medical societies including the AAN, American College of Rheumatology, Infectious Diseases Society of America, and American Academy of Pediatrics agreed that "there are no data to support a causal relationship between tick-borne infections and childhood developmental delay or behavioral disorders (such as attention deficit-hyperactivity disorder, [PANDAS], learning disabilities, or psychiatric disorders)" Some advocates had claimed that Lyme disease caused PANDAS, contrary to evidence.

Society and culture

The debate surrounding the PANDAS hypothesis has societal implications; the media and the Internet have played a role in the PANDAS controversy. The news and other media report the difficulties of families who believe their children have PANDAS or PANS. Attempts to influence public policy have been advanced by advocacy networks such as the USA-based PANDAS Network and Canadian PANDASHELP.

Swerdlow (2005) summarized the societal implications of the hypothesis, and the role of the Internet in the debate surrounding the PANDAS hypothesis: ::quote ... perhaps the most controversial putative TS trigger is exposure to streptococcal infections. The ubiquity of strep throats, the tremendous societal implications of over-treatment (e.g., antibiotic resistance or immunosuppressant side effects) versus medical implications of under-treatment (e.g., potentially irreversible autoimmune neurologic injury) are serious matters. With the level of desperation among Internet-armed parents, this controversy has sparked contentious disagreements, too often lacking both objectivity and civility. ::

Murphy, Kurlan and Leckman (2010) discussed the influence of the media and the Internet in a paper that proposed a "way forward" with the "group of disorders collectively described as PANDAS":Of concern, public awareness has outpaced our scientific knowledge base, with multiple magazine and newspaper articles and Internet chat rooms calling this issue to the public's attention. Compared with ~ 200 reports listed on Medline—many involving a single patient, and others reporting the same patients in different papers, with most of these reporting on subjects who do not meet the current PANDAS criteria—there are over 100,000 sites on the Internet where the possible Streptococcus–OCD–TD relationship is discussed. This gap between public interest in PANDAS and conclusive evidence supporting this link calls for increased scientific attention to the relationship between GAS and OCD/tics, particularly examining basic underlying cellular and immune mechanisms.

History

PANDAS was first described in 1998 by Susan Swedo and a group of researchers at the US National Institute of Mental Health (a branch of the NIH). A similar clinical picture was proposed for PITANDs (pediatric infection-triggered autoimmune neuropsychiatric disorders) for those who met the Swedo et al. criteria for PANDAS, but with symptoms triggered by an infection other than GAS.

Michael Pichichero (2009) noted several reasons that PANDAS had not been validated as a disease classification. Its proposed age of onset and clinical features reflected a particular group of patients chosen for research studies, with no systematic studies of the possible relationship of GAS to other neurologic symptoms. There was dispute over whether its symptom of choreiform movements was distinct from the similar movements of SC. It was not known whether the pattern of abrupt onset was specific to PANDAS. Finally, there was controversy over whether a temporal relationship between GAS infections and PANDAS symptoms existed.

In light of controversies in establishing a basis for the hypothesis, a 2010 paper calling for "a way forward", Murphy, Kurlan and Leckman said: "It is time for the National Institutes of Health, in combination with advocacy and professional organizations, to convene a panel of experts not to debate the current data, but to chart a way forward. For now we have only to offer our standard therapies in treating OCD and tics, but one day we may have evidence that also allows us to add antibiotics or other immune-specific treatments to our armamentarium."

By 2012, with limitations of the PANDAS hypothesis published, the broader pediatric acute-onset neuropsychiatric syndrome (PANS) was proposed (also by Swedo and colleagues, following a conference) to create a better defined condition for research purposes. It describes individuals with eating disorders or rapid onset of OCD along with other neuropsychiatric symptoms, and postulates that the causes can be other than GAS. Whether the PANS hypothesis defines a distinct entity is unclear .

Swedo retired from the NIH in 2019, but serves on the scientific advisory board of the PANDAS Physician Network.

Notes

References

| DiseasesDB = | ICD10 = | ICD9 = | ICDO = | OMIM = | OMIM_mult = | MedlinePlus = | eMedicineSubj = | eMedicineTopic = | eMedicine_mult = | MeshID = C537163 | Orphanet=66624

References

1. (August 2024). "Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS): Immunological Features Underpinning Controversial Entities". Children.
2. (January 2021). "Immunological dysfunction in Tourette syndrome and related disorders". Int J Mol Sci.
3. (2023). "Neuroinflammation, Gut-Brain Axis and Immunity in Neuropsychiatric Disorders". Springer.
4. (October 2023). "Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS): Myth or Reality? The State of the Art on a Controversial Disease". Microorganisms.
5. (May 2019). "PANDAS/PANS in childhood: Controversies and evidence". Paediatr Child Health.
6. (July 2018). "Immune system and obsessive-compulsive disorder". Psychoneuroendocrinology.
7. (March 2018). "CANS: Childhood acute neuropsychiatric syndromes". Eur J Paediatr Neurol.
8. (February 1998). "Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases". Am J Psychiatry.
9. (2008). "Tourette syndrome and obsessive–compulsive disorder". Brain Dev.
10. (2009). "Symptom dimensions and subtypes of obsessive-compulsive disorder: a developmental perspective". Dialogues Clin Neurosci.
11. (October 2021). "European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part I: assessment". Eur Child Adolesc Psychiatry.
12. (February 2019). "Streptococcal Infections and Exacerbations in PANDAS: A Systematic Review and Meta-analysis". Pediatr Infect Dis J.
13. (November 2024). "IL-17 in serum and cerebrospinal fluid of pediatric patients with acute neuropsychiatric disorders: Implications for PANDAS and PANS". Eur J Paediatr Neurol.
14. Boileau B. (2011). "A review of obsessive-compulsive disorder in children and adolescents". Dialogues Clin Neurosci.
15. (August 2011). "Neurobiology of Tourette syndrome: current status and need for further investigation". J. Neurosci..
16. Pichichero ME. (2009). "Hot Topics in Infection and Immunity in Children V". Springer.
17. Giavannoni G. (2006). "PANDAS: overview of the hypothesis". Lippincott Williams & Wilkins.
18. (December 2017). "Tics and Tourette: a clinical, pathophysiological and etiological review". Curr Opin Pediatr.
19. Robertson MM. (February 2011). "Gilles de la Tourette syndrome: the complexities of phenotype and treatment". Br J Hosp Med (Lond).
20. Singer HS. (2011). "Hyperkinetic Movement Disorders". Elsevier.
21. "Susan Swedo, M.D.". American Psychiatric Association.
22. (February 2020). "Obsessive-compulsive disorder in children and adolescents: epidemiology, diagnosis and management". Transl Pediatr.
23. (September 2019). "Inflammation in Tic Disorders and Obsessive-Compulsive Disorder: Are PANS and PANDAS a Path Forward?". J Child Neurol.
24. (April 2021). "Consensus statement on childhood neuropsychiatric presentations, with a focus on PANDAS/PANS". British Paediatric Neurology Association.
25. (May 2021). "8E4A.0 Paraneoplastic or Autoimmune Disorders of the Central Nervous System, Brain or Spinal Cord". World Health Organization.
26. (July 2021). "European clinical guidelines for Tourette syndrome and other tic disorders: summary statement". Eur Child Adolesc Psychiatry.
27. (November 2017). "Biomarkers for diagnosis of Pediatric Acute Neuropsychiatric Syndrome (PANS) - Sensitivity and specificity of the Cunningham Panel". J Neuroimmunol.
28. (December 2017). "Corrigendum to Biomarkers for diagnosis of Pediatric Acute Neuropsychiatric Syndrome (PANS) - Sensitivity and specificity of the Cunningham Panel [J. Neuroimmunol. 312. (2017) 31-37]". J Neuroimmunol.
29. (April 2009). "Children with obsessive-compulsive disorder: are they just "little adults"?". J. Clin. Invest..
30. (September 2017). "Clinical management of pediatric acute-onset neuropsychiatric syndrome: part II—use of immunomodulatory therapies". J Child Adolesc Psychopharmacol.
31. (September 2017). "Clinical management of pediatric acute-onset neuropsychiatric syndrome: part III—treatment and prevention of infections". J Child Adolesc Psychopharmacol.
32. UK PANDAS & PANS Physicians Network. (November 2018). "PANDAS & PANS Treatment Guidelines (v1.6)". e-hospital.co.uk.
33. (April 2021). "Clinical guidance for diagnosis and management of suspected Pediatric Acute-onset Neuropsychiatric Syndrome in the Nordic countries". Acta Paediatr.
34. (2021). "Anti-inflammatory, antibacterial and immunomodulatory treatment in children with symptoms corresponding to the research condition PANS (Pediatric Acute-onset Neuropsychiatric Syndrome): A systematic review". PLOS ONE.
35. (January 2011). "Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology.
36. (April 2006). "Contemporary assessment and pharmacotherapy of Tourette syndrome". NeuroRx.
37. (June 2021). "A Comprehensive Review of Tic Disorders in Children". J Clin Med.
38. TAA PANDAS/PANS Workgroup. "PANDAS/PANS and Tourette Syndrome (Disorder)". Tourette Association of America.
39. (March 2009). "Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics". Circulation.
40. (January 2021). "Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease". Clinical Infectious Diseases.
41. Swerdlow NR. (September 2005). "Tourette syndrome: current controversies and the battlefield landscape". Curr Neurol Neurosci Rep.
42. (August 2010). "The immunobiology of Tourette's disorder, pediatric autoimmune neuropsychiatric disorders associated with Streptococcus, and related disorders: a way forward". J Child Adolesc Psychopharmacol.
43. (March 2018). "Treatment of PANDAS and PANS: a systematic review". Neurosci Biobehav Rev.
44. (December 2011). "Moving from PANDAS to CANS". J Pediatr.
45. Borrell, Brendan. (January 2020). "How a controversial condition called PANDAS is gaining ground on autism". Simons Foundation.

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::